VIKRAM SINHA, PhD, FACP
IQ Clinical Pharmacology Leadership Group (CPLG) Chair (2020-2021)
IQ CPLG Member (2017-present)
IQ Communications Committee Member (2018-2021)
Vice President, Global Head Quantitative Clinical Pharmacology, Takeda
PhD, Pharmaceutical Sciences, University of Arizona
WHAT BENEFITS HAVE YOU AND YOUR COMPANY ENJOYED AS MEMBERS OF IQ?
IQ is very productive and well-managed. My company and colleagues can address common issues and challenges in a noncompetitive space. All issues that are of interest get a platform for discussion. Leadership opportunities have provided visibility to my colleagues and their talents.
WHAT FACTORS HELP SHAPE THE GROWTH OF IQ?
IQ member companies are very committed to advancing science. They see great synergy in a pre (non)-competitive environment and have an opportunity to advance topics, especially those of interest to their individual organization. It is very influential and impactful when experts come together and advance a scientific position, best practices, etc. In parallel, the advent of newer modalities – gene treatments, cell-based therapies is a clarion call for a quick and steep learning curve.
WHAT IQ ACCOMPLISHMENTS MAKE YOU MOST PROUD?
In my tenure with CPLG, the sustained outreach with the FDA and PMDA have been very impactful. The working group publications have been well received. Serving as Chair is a privilege and an honor. IQ has provided an opportunity for my company and colleagues to participate and advance pharmaceutical innovation.